GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
The company is also not currently profitable, although as of the latest quarter, it is sitting on a healthy $706 million in cash reserves
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
The fact that dosage increases do not raise your monthly cost is a genuine advantage, especially since most tirzepatide dosing protocols involve titrating up over several months
There should be more tolerance of the fact that you can be very healthy at a range of weights, Dushay says
Instead, theyre designed to allow room for therapy to treat the conditions underlying cause
